Table 2.
Comparison of proliferative responses to different categories of recall antigens before and after initiation of HAART. Each patient was assessed for proliferative responses following initiation of HAART at the single timepoint at which their responses peaked. Ten patients peaked at week 16. Six patients peaked at week 12. Six patients peaked at week 8. Seven patients peaked at week 4. No patients peaked at week 2 and 1 patient peaked at week 1. Four patients failed to demonstrate any positive responses to antigenic stimulus following initiation of HAART
| Number of patients responding | ||
|---|---|---|
| At baseline (%) | Following initiation of HAART (%) | |
| Transient antigens | ||
| PPD | 8 (22) | 17 (47) |
| FLU | 7 (19) | 17 (47) |
| Tetanus | 11 (31) | 15 (42) |
| Persistent antigens | ||
| HSV | 17 (47) | 27 (75) |
| CMV | 10 (28)* | 21 (60)* |
| Candida | 11 (31) | 24 (67) |
| HIV-1 p24 | 2 (6) | 10 (27) |
| HIV-1 gp120 | 2 (6) | 11 (31) |
| HIV-1 nef | 2 (6) | 19 (7) |
*
Patient 1 was not assessed for CMV responses, thus the sample size for CMV was 35 patients.